iifl-logo

Biocon Ltd Cash Flow Statement

355.7
(0.37%)
Jun 30, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Biocon FINANCIALS

Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

139.7

358.8

388.5

305.8

Depreciation

-108.2

-103.5

-98

-136.1

Tax paid

-53.6

-78.3

-111.9

-67.3

Working capital

268.3

64.09

379.5

-311.6

Other operating items

Operating

246.2

241.1

558.1

-209.2

Capital expenditure

171.6

104.8

-243.4

107.8

Free cash flow

417.8

345.9

314.7

-101.4

Equity raised

14,713.9

13,963.9

13,235

12,901.2

Investing

-132.7

459.9

753.8

310.8

Financing

80

7.1

-123.4

7.3

Dividends paid

0

0

0

60

Net in cash

15,079

14,776.8

14,180.1

13,177.9

Biocon : related Articles

Top Stocks for Today - 20th June 2025
20 Jun 2025|06:07 AM

Here are some of the stocks that may see significant price movement today: United Spirits, Biocon, NATCO Pharma, etc.

Read More
Top Stocks for Today - 17th June 2025
17 Jun 2025|06:35 AM

Here are some of the stocks that may see significant price movement today: Hyundai Motor, Biocon, Zee Entertainment, etc.

Read More
Biocon Opens ₹4,500 Crore QIP with Floor Price Fixed at ₹340.20 Per Share
16 Jun 2025|09:52 PM

Biocon has appointed Kotak Mahindra Capital, Goldman Sachs (India), and BofA Securities India as lead advisors for the transaction

Read More
Biocon gets six-month extension on insulin supply pact
22 May 2025|12:42 PM

In its filing with the bourses, the company reported that the current contract period of 36 months has been extended for an additional six months.

Read More
Biocon shares zoom ~2% after drug launch in Japan
21 May 2025|11:41 AM

As per the company’s filing with the bourses, Biocon Biologics has developed and manufactured this injection while Yoshindo Inc.

Read More
Biocon Q4 Net Profit Soars 154% YoY to ₹344.5 Crore
11 May 2025|08:59 AM

The operating performance was also good as EBITDA increased 17.7% to ₹1,078.2 crore in March quarter compared with ₹915.9 crore in Q4 FY24.

Read More
Biocon Biologics Secures Multiple Market Access for Yesintek
5 May 2025|03:48 PM

Yesintek has been added to Express Scripts' National Preferred Formulary (NPF), effective March 21, 2025.

Read More
Biocon to Raise ₹4,500 Crore; Approves Capital Expansion Plan
24 Apr 2025|09:50 PM

The fundraising may be executed in one or more tranches using QIP, rights issues, or any other permissible route under regulatory guidelines.

Read More
Top Stocks for Today - 24th April 2025
24 Apr 2025|06:20 AM

Here are some of the stocks that may see significant price movement today: LTIMindtree, Dalmia Bharat, Bajaj Housing, etc.

Read More
Biocon unit expands oncology portfolio after USFDA approval
11 Apr 2025|09:00 AM

Jobevne is a vascular endothelial growth factor (VEGF) impediment that sticks with VEGF and restrain the interaction with its receptors.

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.